mRNA Electroporated Autologous Dendritic Cells for Stage III/IV Melanoma

Malignant Melanoma Stage IV Clinical Trial

— DC-MEL  

Official title:

Randomized Controlled Phase II Clinical Trial on mRNA Electroporated Autologous Dendritic Cells for Stage III/IV Melanoma Patients Who Are Disease-free Following the Local Treatment of Macrometastases.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01676779
• Other study ID #: DC-MEL
• Status: Completed
• Phase: Phase 2
• First received: August 21, 2012
• Last updated: May 23, 2017
• Start date: October 2012
• Est. completion date: September 2016

Study information

• Verified date: May 2017
• Source: Universitair Ziekenhuis Brussel
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open label, 2-arm, 1-stage, randomized controlled phase II study in patients with AJCC stage IIIB/C & -IV melanoma. At baseline tumor assessment (using total body FDG-PET/CT), patients should be free from measurable tumor lesions (according to RECISTv1.1 definitions) following prior local therapy (e.g. following surgical resection, isolated limb perfusion, radiofrequency ablation, cryotherapy, radiotherapy, electrochemotherapy, …). Patients should not have symptomatic non-measurable tumor lesions (e.g. bone metastasis, or pleural effusion), and lesions treated by prior local therapy should be free from progression. Patients should not have received any prior systemic therapy (non-experimental or experimental).

Description:

This is an open label, 2-arm, 1-stage, randomized controlled phase II study in patients with AJCC stage IIIB/C & -IV melanoma. At baseline tumor assessment (using total body FDG-PET/CT), patients should be free from measurable tumor lesions (according to RECISTv1.1 definitions) following prior local therapy (e.g. following surgical resection, isolated limb perfusion, radiofrequency ablation, cryotherapy, radiotherapy, electrochemotherapy, …). Patients should not have symptomatic non-measurable tumor lesions (e.g. bone metastasis, or pleural effusion), and lesions treated by prior local therapy should be free from progression. Patients should not have received any prior systemic therapy (non-experimental or experimental).

• Patients will be randomized between two treatment arms (Arm-A and -B). In study Arm-A, patients will receive DC-administrations during one year following randomization. Salvage treatment by local therapies will be allowed during the study treatment in Arm-A. In study Arm-B, patients will initiate DC-administrations only after documented recurrence of the melanoma that cannot be salvaged by local therapy.

• The primary endpoint of this clinical trial is to determine the rate (%) of patients who are free from macrometastases (: measurable tumor lesions and symptomatic non-measurable tumor lesions) at 1-year (= 52 weeks) after randomization.

Patients treated on Arm-B will serve as a contemporary control-arm to help interpreting the outcome of patients treated in Arm-A. By design (phase II) this trial will not be powered to statistically prove a predefined difference between the two study arms (this would require a phase III design). Patients treated in Arm-B will be able to initiate immunotherapy with autologous DC at the time of recurrence that can not be salvaged by local therapy. Documentation of the anti-tumor activity and survival following DC-treatment at recurrence in Arm-B patients will be a secondary objective of this clinical trial.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 88
• Est. completion date: September 2016
• Est. primary completion date: September 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Able and willing to give written informed consent

2. Histological documentation of AJCC stage III or stage IV melanoma

3. melanoma (melanoma originating in the choroid, iris or ciliar body are not eligible)

4. baseline tumor assessment by whole-body FDG-PET/CT, patients should be free from measurable tumor lesions (RECIST (v1.1)), and free from symptomatic non-measurable tumor lesions

5. Prior local treatment of primary and metastatic tumor lesions is allowed . Treated tumor lesions should be free from progression at baseline assessment

6. Normal organ function and normal hematological parameters;laboratory parameters should be within normal range, except following laboratory parameters:HEMOGLOBIN = 10 G/DL; GRANULOCYTES = 1,500/µL; LYMPHOCYTES = 1000/µL; PLATELETS = 100,000/µL; SERUM CREATININ = 2.0 MG/DL; SERUM BILIRUBIN = 2.0 MG/DL; AST AND ALT = 2 X THE NORMAL UPPER LIMITS; LDH = 1,5X NORMAL UPPER LIMIT; CRP = 1,5X NORMAL UPPER LIMIT; PROTHROMBIN TIME (PT) INTERNATIONAL NORMALIZED RATIO (INR) AND PARTIAL THROMBOPLASTIN TIME (PTT) WITHIN NORMAL LIMITS

7. Negative serology for HCV, and HIV; absence of active infection with HBV, and Syphilis; If positive results for HepB or Syphilis indicate immunity and are not indicative of active infection, the patient can enter the study.

8. Adequate venous access(to undergo leukapheresis)

9. No prior systemic therapy for melanoma

10. Full recovery from all prior therapies. A period of 4 weeks following major surgery, radiation therapy, or ILP, or any other major invasive procedure is required

11. Baseline WHO performance status of 0 or 1

12. Male and female patients = 18 years

13. No need for uninterrupted therapeutic anticoagulation

14. No prior history of a serious autoimmune disorder

15. No concomitant medication with immune suppressive drugs

16. Women of childbearing potential must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 8 weeks after the study in such a manner that the risk of pregnancy is minimized.

Exclusion Criteria:

1. Evidence of immunodeficiency or autoimmune disease requiring medical treatment (e.g. corticosteroids or other immunosuppressive drugs).Vitiligo is not an exclusion criterion

2. Any serious acute or chronic illnesses (e.g. heart disease NYHA Class III or IV,renal-,liver- or pulmonary insufficiency) or other conditions requiring concurrent medications not allowed during this study (e.g. active chronic infections requiring antibiotics)

3. History of malignancy. Curatively treated cervical carcinoma in situ,or squamous-,or basal cell carcinoma of the skin, or subjects who have been treated and recurrence-free of other malignancies for more than 5 years following the diagnosis are eligible

4. Inability to undergo FDG-PET/CT, or MRI examination

5. Mental impairment that may compromise the ability to give informed consent and comply with the requirements of the study

6. Participation in any other clinical trial involving another investigational agent within 4 weeks prior to enrollment

7. Subject is pregnant (positive serum beta-HCG test at screening) or is currently breast-feeding, anticipates becoming pregnant/impregnating their partner during the study or within 6 months after study participation, or subject does not agree to follow acceptable methods of birth control, to avoid conception during the study and for at least 6 months after receiving the last dose of study treatment

8. Current alcohol dependence or drug abuse

9. Known hypersensitivity to the study treatment

10. Legal incapacity or limited legal capacity

11. Presence of any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.

12. Signs and symptoms suggestive of transmissible spongiform encephalopathy,or family members who suffer(ed) from such.

Related Conditions & MeSH terms

• Malignant Melanoma Stage III
• Malignant Melanoma Stage IV
• Melanoma

Intervention

Biological:
• Dendritic cell therapy
Dendritic cell therapy IV and ID

Locations

Country	Name	City	State
Belgium	UZ Brussel	Brussel

Sponsors (2)

Lead Sponsor	Collaborator
Universitair Ziekenhuis Brussel	RIZIV

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	1-year disease free survival percentage	Patients will be evaluated 52 weeks following randomization for their melanoma disease status (= macro-metastases present or absent)	1-year following recruitment date
Secondary	safety	Patients will be followed continuous during their study participation for adverse events	continuous during the study (52weeks after start)